Reducing Vancomycin Dosage in Children on ECMO with Renal Impairment

Abstract

Background Extracorporeal membrane oxygenation (ECMO) can influence pharmacokinetics. We investigated the vancomycin dosage in children on ECMO compared to critically ill children to determine the necessary dosage adjustment on ECMO.

Methods Eight-year, single-center, retrospective cohort study at a tertiary heart center's pediatric cardiac intensive care unit (ICU) of children undergoing ECMO support. Our control group (non-ECMO) was critically ill children with delayed sternal closure after cardiac surgery. We included consecutively all children undergoing vancomycin administration. The starting dose was 10 to 15 mg/kg BW per dose, every 8 to 12 hours depending on age. The vancomycin trough level was maintained in the 10 to 20 μg/ml range.

Results 85 total courses on ECMO and 99 non-ECMO courses were included. The ECMO group's daily vancomycin dose was significantly lower than non-ECMO's at a median of 33.3 and 38.5 mg/kg/d, respectively (p < 0.001). Vancomycin serum trough levels were similar between groups and within the target range. The ECMO group's daily vancomycin dose dropped faster over time, with a dose on day 3 of 28.7 and 33.7 mg/kg/d, respectively. The impact of renal function on vancomycin dosing was more apparent in the ECMO group. If the renal function was reduced at the start of treatment, the vancomycin dose was lower in the ECMO group compared to the non-ECMO group with renal impairment (22.5 vs. 42.1 mg/kg/d; p < 0.001). When renal function was normal, the doses were similar between groups.

Conclusion In children on ECMO with impaired renal function at treatment initiation, lower vancomycin doses were necessary. Early therapeutic drug monitoring, even before reaching a steady state, should be considered.

Keywords

extracorporeal membrane oxygenation - ECMO - pediatric - kidney - pharmacokinetics - intensive care

Publikationsverlauf

Eingereicht: 27. Mai 2024

Angenommen: 19. September 2024

Artikel online veröffentlicht:
21. November 2024

• References

• 1 Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 2012; 27 (06) 741.e9-741.e18
• 2 Pokorná P, Šíma M, Tibboel D, Slanař O. Impact of haemolysis on vancomycin disposition in a full-term neonate treated with extracorporeal membrane oxygenation. Perfusion 2021; 36 (08) 864-867
• 3 Hatachi T, Sofue T, Ito Y. et al. Antibiotic prophylaxis for open chest management after pediatric cardiac surgery. Pediatr Crit Care Med 2019; 20 (09) 801-808
• 4 Gijsen M, Vlasselaers D, Spriet I, Allegaert K. Pharmacokinetics of antibiotics in pediatric intensive care: fostering variability to attain precision medicine. Antibiotics (Basel) 2021; 10 (10) 10
• 5 Colin PJ, Allegaert K, Thomson AH. et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Clin Pharmacokinet 2019; 58 (06) 767-780
• 6 Elassal AA, Eldib OS, Dohain AM, Abdelmohsen GA, Abdalla AH, Al-Radi OO. Delayed sternal closure in congenital heart surgery: a risk-benefit analysis. Heart Surg Forum 2019; 22 (05) E325-E330
• 7 Wang S, Izer JM, Clark JB. et al. In vivo hemodynamic performance evaluation of novel electrocardiogram-synchronized pulsatile and nonpulsatile extracorporeal life support systems in an adult swine model. Artif Organs 2015; 39 (07) E90-E101
• 8 López-Herce J, Casado E, Díez M. et al. Renal function in children assisted with extracorporeal membrane oxygenation. Int J Artif Organs 2020; 43 (02) 119-126
• 9 Swaniker F, Kolla S, Moler F. et al. Extracorporeal life support outcome for 128 pediatric patients with respiratory failure. J Pediatr Surg 2000; 35 (02) 197-202
• 10 Fleming GM, Askenazi DJ, Bridges BC. et al. A multicenter international survey of renal supportive therapy during ECMO: the Kidney Intervention During Extracorporeal Membrane Oxygenation (KIDMO) group. ASAIO J 2012; 58 (04) 407-414
• 11 Kielstein JT, Czock D, Schöpke T. et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34 (01) 51-56
• 12 Himebauch AS, Kilbaugh TJ, Zuppa AF. Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review. Expert Opin Drug Metab Toxicol 2016; 12 (10) 1133-1142
• 13 Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D. Determinants of drug absorption in different ECMO circuits. Intensive Care Med 2010; 36 (12) 2109-2116
• 14 An SH, Lee EM, Kim JY, Gwak HS. Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation. Eur J Hosp Pharm 2020; 27 (e1): e25-e29
• 15 Davies SW, Guidry CA, Petroze RT, Hranjec T, Sawyer RG. Vancomycin and nephrotoxicity: just another myth?. J Trauma Acute Care Surg 2013; 75 (05) 830-835
• 16 Hanrahan TP, Harlow G, Hutchinson J. et al. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*. Crit Care Med 2014; 42 (12) 2527-2536
• 17 Kao LS, Fleming GM, Escamilla RJ, Lew DF, Lally KP. Antimicrobial prophylaxis and infection surveillance in extracorporeal membrane oxygenation patients: a multi-institutional survey of practice patterns. ASAIO J 2011; 57 (03) 231-238
• 18 Biffi S, Di Bella S, Scaravilli V. et al. Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention. Int J Antimicrob Agents 2017; 50 (01) 9-16
• 19 Barbaro RP, Paden ML, Guner YS. et al; ELSO member centers. Pediatric Extracorporeal Life Support Organization Registry International Report 2016. ASAIO J 2017; 63 (04) 456-463
• 20 Liu C, Bayer A, Cosgrove SE. et al; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52 (03) e18-e55